All relevant data are within the paper and its Supporting Information files.

Introduction {#sec001}
============

The majority of emerging infectious diseases are zoonotic and arise by the acquisition of mutations that permit the infection of humans \[[@pbio.3000490.ref001]\]. Notable examples are viruses such as influenza and HIV, but also include parasites such as *P*. *falciparum*, which causes the most severe form of malaria \[[@pbio.3000490.ref002]\]. *Plasmodium* parasites have evolved to infect many different species of animal, including mammals, birds, and reptiles, and are often restricted to their known hosts \[[@pbio.3000490.ref003]\]. While ecological factors are likely to play an important role in *Plasmodium* host restriction in the wild, laboratory experiments show that molecular barriers also exist \[[@pbio.3000490.ref004]\]. Our understanding of the molecular pathways involved in *Plasmodium* host switching are not well understood but could be used to help predict and preempt future zoonoses that may result in deadly pandemics.

*P*. *falciparum* malaria is a devastating infectious disease that is one of the world's major health problems and is still responsible for over 400,000 deaths annually \[[@pbio.3000490.ref005]\]. The origin of *P*. *falciparum* was recently shown to be the *Laverania*: a subgenus of parasites that infect African great apes, and which exhibit a strict tropism for their hosts. Beyond *P*. *falciparum*, the *Laverania* contains six other species, of which three, *P*. *gaboni*, *P*. *reichenowi*, and *P*. *billcollinsi*, infect only chimpanzees; and the remaining three, *P*. *adleri*, *P*. *blacklocki*, and *P*. *praefalciparum*, exclusively infect gorillas \[[@pbio.3000490.ref006],[@pbio.3000490.ref007]\]. *P*. *falciparum* is most closely related to the gorilla-restricted parasite *P*. *praefalciparum*, diverging from their most recent common ancestor between forty and sixty thousand years ago, at around the same time as the expansion of humans out of Africa \[[@pbio.3000490.ref008]\]. Phylogenetically, the *Laverania* separate into two distinct clades (A and B), and genome comparisons highlighted a rare inter-clade introgression of an approximately 8-kbp genomic region from an ancestor of *P*. *adleri* to the precursor of *P*. *falciparum*/*P*. *praefalciparum* \[[@pbio.3000490.ref008],[@pbio.3000490.ref009]\] ([Fig 1A](#pbio.3000490.g001){ref-type="fig"}). Introgressions are the transfer of genomic regions from one species into another, caused by hybridization followed by recurrent crossing between the hybrid and its descendants and the parental species. The introgressed region encoded two members of a protein complex that is essential for invasion of erythrocytes: reticulocyte-binding protein homologue 5 (RH5) and cysteine-rich protective antigen (CyRPA) ([S1 Fig](#pbio.3000490.s001){ref-type="supplementary-material"}), suggesting it may have been important in the zoonotic origin of *P*. *falciparum*.

![RH5 from an ancient inter-clade introgression in *Laverania* parasites binds both human and gorilla basigin.\
**(A)** Phylogenetic relationships and host tropisms of the parasites within the *Laverania* subgenus. The inter-clade introgression event encoding *rh5* and *cyrpa* is marked with a yellow arrow. Hosts are indicated as chimpanzee (blue), gorilla (black), and human (red) icons. **(B)** Organization of the RH5 invasion complex. RH5 is tethered through its N terminus (RH5Nt) to the parasite surface via P113 and binds host basigin on the erythrocyte surface; CyRPA directly interacts with RH5, thereby recruiting RIPR to the complex. **(C)** Ancestral introgressed RH5 binds to gorilla and human, but not chimpanzee, basigin. Serial dilutions of the indicated concentrations of purified introgressed RH5 were injected over gorilla, human, and chimpanzee basigin immobilized on a sensor chip. Raw surface plasmon resonance (SPR) traces are shown in black and fitted to a simple 1:1 Langmuir binding isotherm (red) to derive the equilibrium dissociation constants (*K*~D~s). Underlying numerical data can be found in [S1 Data](#pbio.3000490.s009){ref-type="supplementary-material"}. A representative experiment of three is shown. BSG, basigin; *cyrpa*, cysteine-rich protective antigen; RH5, reticulocyte-binding protein homologue 5; RH5Ct, RH5 C-terminal domain; RH5Nt, RH5 N-terminal domain; RIPR, RH5-interacting protein; SPR, surface plasmon resonance.](pbio.3000490.g001){#pbio.3000490.g001}

RH5 is a member of the *P*. *falciparum* reticulocyte-binding homologue (Rh) family of ligands, which are released by the parasite during invasion and are required for host cell recognition by directly interacting with receptor proteins displayed on the erythrocyte surface \[[@pbio.3000490.ref010]\]. RH5 differs from the other members of the Rh family because it encodes a secreted rather than membrane-tethered protein and cannot be genetically deleted in any *P*. *falciparum* strain, demonstrating that it is essential for parasite growth in blood stage culture \[[@pbio.3000490.ref010]\]. Once released at the point of invasion, RH5 is tethered to the parasite surface by direct interactions with the membrane-anchored protein P113 \[[@pbio.3000490.ref011]\]. RH5 was found to be part of a larger protein complex, and immunoprecipitation followed by mass spectrometry identified two other secreted parasite proteins: CyRPA \[[@pbio.3000490.ref012]\] and RH5-interacting protein (RIPR) \[[@pbio.3000490.ref013]\] ([Fig 1B](#pbio.3000490.g001){ref-type="fig"}). Subsequent biochemical binding studies \[[@pbio.3000490.ref011]\] and then structural work \[[@pbio.3000490.ref014]\] on the complex have revealed that only CyRPA bound both RH5 and RIPR, demonstrating that it acts as a central organizer of the complex. Using an assay developed to detect extracellular protein interactions \[[@pbio.3000490.ref015]\], the host erythrocyte receptor for RH5 was identified as basigin, and this interaction is both essential and universally required by all strains of *P*. *falciparum* for invasion \[[@pbio.3000490.ref016]\], making RH5 and the other components of the complex important blood stage vaccine targets \[[@pbio.3000490.ref017]\].

One puzzling evolutionary aspect of the RH5 invasion complex is that obvious sequence orthologues of each component do not co-occur in the genomes of sequenced *Plasmodium* genomes. Genes encoding P113 and RIPR are present in both primate and rodent-infecting parasite species, while *CyRPA* is present in primate but not rodent parasites. RH5 and the use of basigin as an essential erythrocyte invasion receptor appear to be recent evolutionary innovations because genes encoding RH5 proteins are restricted to the *Laverania* and basigin is not essentially required for erythrocyte invasion by either *P*. *vivax* or *P*. *knowlesi* \[[@pbio.3000490.ref018]\]. Variants of RH5 in *P*. *falciparum* have been shown to have roles in host-specific invasion \[[@pbio.3000490.ref019],[@pbio.3000490.ref020]\], and the inability of *P*. *falciparum* RH5 to bind gorilla and only weakly to chimpanzee basigin suggested the RH5--basigin interaction was responsible for the restriction of *P*. *falciparum* to humans \[[@pbio.3000490.ref021]\]. It was widely thought, therefore, that host restriction in Laveranian parasites was determined by the specificity of the RH5--basigin interaction and that the transfer of this gene from *P*. *adleri* into the ancestor of *P*. *falciparum*/*P*. *praefalciparum* was the founding event leading to the evolution of one of the most deadly human parasites, *P*. *falciparum* \[[@pbio.3000490.ref008]\].

By comparing the binding properties of extant and calculated ancestral sequences of the RH5 invasion complex within the *Laverania* subgenus, here we show that a crucial property of the introgressed RH5 was the ability to bind both gorilla and human basigin receptors. Using mutational analysis, we demonstrate that a single residue in RH5 can explain the subsequent restriction of *P*. *falciparum* to humans, thereby revealing a molecular pathway for the zoonotic origin of *P*. *falciparum* malaria.

Results {#sec002}
=======

To investigate how the inter-clade transfer of genetic material encoding RH5 contributed to the zoonotic origin of *P*. *falciparum* in humans, we determined, using probabilistic-based approaches and the known sequences of the extant species, the likely sequence of the introgressed ancestral *rh5* gene. Our analysis converged on a single protein sequence (introgressed ancestral RH5 \[IntRH5\]) with very high confidence at each residue ([S1 Table](#pbio.3000490.s007){ref-type="supplementary-material"}). A synthetic gene corresponding to this sequence was constructed, and expressed as a recombinant protein in mammalian cells ([S2 Fig](#pbio.3000490.s002){ref-type="supplementary-material"}). The protein was purified and the biophysical binding parameters to human, gorilla, and chimpanzee basigin were quantified using surface plasmon resonance (SPR). Remarkably, we observed that the introgressed RH5 bound both human and gorilla basigin with comparable affinities ([Fig 1C](#pbio.3000490.g001){ref-type="fig"}); no binding was detected to chimpanzee basigin. We confirmed the ability of the introgressed RH5 protein to specifically bind human basigin in the context of a cell membrane by using a well-characterized RH5 cell surface binding assay \[[@pbio.3000490.ref022]\] ([S3 Fig](#pbio.3000490.s003){ref-type="supplementary-material"}). Biotinylated RH5 was clustered around a fluorescent streptavidin conjugate to create a highly avid fluorescent binding probe, which was incubated with human erythroid-like (HEL) cells. The RH5 probe bound cell surface basigin, causing a shift in the fluorescence signal when analyzed by flow cytometry; the binding specificity for the basigin receptor was determined by preincubating the cells with an anti-basigin monoclonal antibody that prevented binding. This promiscuous binding tropism is in striking contrast to the restriction of *P*. *falciparum* RH5 for human basigin \[[@pbio.3000490.ref021]\] and suggested a plausible mechanism for the zoonotic infection of humans by a gorilla parasite.

We next asked if this promiscuous host receptor binding was a unique property of the ancestral introgressed RH5 by determining the RH5--basigin receptor--ligand tropisms across the extant *Laverania* parasites. We cloned, expressed, and purified the RH5 orthologues from six *Laverania* parasites ([S2 Fig](#pbio.3000490.s002){ref-type="supplementary-material"}) and systematically quantified their binding affinities to human, gorilla, and chimpanzee basigin. The RH5 orthologues from all *Laverania* parasites bound their respective host basigin receptors, showing that the RH5--basigin interaction is conserved across the *Laverania* and that the proteins were correctly folded and functional ([Fig 2A](#pbio.3000490.g002){ref-type="fig"}). Like *P*. *falciparum*, the RH5 proteins from the clade B parasites *P*. *reichenowi* and *P*. *billcollinsi* bound only to the basigin receptor from their known host ([Fig 2A](#pbio.3000490.g002){ref-type="fig"}). However, the RH5 proteins from *P*. *praefalciparum* and both clade A parasites *P*. *gaboni* and *P*. *adleri*, while binding the basigin receptor from their known ape host, also exhibited the same promiscuous binding profile as the introgressed RH5 by additionally binding human basigin ([Fig 2A](#pbio.3000490.g002){ref-type="fig"}). Again, we confirmed these findings using the cell-based RH5 binding assay ([Fig 2B](#pbio.3000490.g002){ref-type="fig"}).

![*P*. *praefalciparum* and clade A *Laverania* RH5 does not exhibit strict host basigin binding specificity.\
**(A)** The binding of *Laverania* RH5 proteins to human, gorilla, and chimpanzee basigin was quantified by SPR. Sensorgram data from serial dilutions of the RH5 proteins are shown in black and were fitted to a simple 1:1 Langmuir binding isotherm (red). Background shading of the graphs indicates where binding was expected based on the known parasite tropism (beige) or were unexpected (gray). **(B)** Binding specificities of *Laverania* parasite RH5 proteins with human basigin were confirmed using an RH5 cell binding assay. Avid RH5 binding probes were presented to basigin-expressing HEL cells, and binding specificity was demonstrated by showing that all RH5 probe binding was abolished if the cells were preincubated with an anti-basigin monoclonal antibody (mAb) that blocks RH5 binding (Ab1---blue histograms) compared with a cell-binding isotype-matched anti-CD59 mAb (red). Control is streptavidin-PE alone (gray). Summary numerical data are provided in [S1 Data](#pbio.3000490.s009){ref-type="supplementary-material"}; gating strategy and original .fcs files in [S2 Data](#pbio.3000490.s010){ref-type="supplementary-material"}. Representative results of at least three independent experiments are shown. Ab1, anti-basigin mAb; HEL, human erythroid-like; IntRH5, introgressed ancestral RH5; mAb, monoclonal antibody; PE, phycoerythrin; RH5, reticulocyte-binding protein homologue 5; SPR, surface plasmon resonance.](pbio.3000490.g002){#pbio.3000490.g002}

During erythrocyte invasion, RH5 interacts with components of a larger protein complex that includes the membrane-tethered P113 protein and two other secreted proteins: CyRPA and RIPR ([Fig 1B](#pbio.3000490.g001){ref-type="fig"}). Interestingly, the introgressed fragment encompassed two genes encoding RH5 complex components: RH5 and CyRPA, which are genetically closely linked ([S1 Fig](#pbio.3000490.s001){ref-type="supplementary-material"}). Was the cotransfer of the gene encoding CyRPA an important factor that permitted human infection? And immediately following the introgression event, could the different components interact to form a functional complex? To address these questions, we again used ancestral sequence reconstruction to determine the sequences of the introgressed CyRPA and ancestral P113 and RIPR ([S1 Table](#pbio.3000490.s007){ref-type="supplementary-material"}). We expressed these proteins as enzymatically monobiotinylated "baits" and multimerized enzyme-tagged "preys" and tested them for the ability to directly interact using an assay called avidity-based extracellular interaction screening (AVEXIS), which is specifically designed to detect extracellular protein interactions \[[@pbio.3000490.ref015]\]. Using this approach, we showed that the introgressed RH5 could interact with both the introgressed CyRPA and ancestral P113 and that the introgressed CyRPA could bind ancestral RIPR ([Fig 3A](#pbio.3000490.g003){ref-type="fig"}). We further showed that the proteins interacted directly and determined their biophysical parameters using SPR ([S4 Fig](#pbio.3000490.s004){ref-type="supplementary-material"}). These results are consistent with the known binding properties of the RH5 complex components \[[@pbio.3000490.ref011]\] and their structural arrangement \[[@pbio.3000490.ref014]\], demonstrating that RH5 and CyRPA encoded on the introgressed fragment could have formed a functional RH5 complex.

![RH5 complex interactions are conserved across the *Laverania*, including the introgressed RH5.\
**(A)** Interactions between the introgressed (Int) and ancestral (Anc) *Laverania* RH5 complex components are conserved. Introgressed RH5 binds introgressed CyRPA and ancestral P113, and introgressed CyRPA binds ancestral RIPR, as shown by the AVEXIS assay using the named bait and prey proteins. Bars represent means ± SEM; *n* = 3. **(B)** Summary of the interactions within the *Laverania* RH5 complex. The orthologues of RH5, P113, and CyRPA from the named *Laverania* species were synthesized, expressed, and systematically tested for binding using the AVEXIS assay. The RH5-CyRPA (upper panel) and RH5-P113 (lower panel) interactions were conserved within (indicated by red boxes) and across all tested species, with the exception of *P*. *billcollinsi* RH5, which did not interact with *P*. *adleri* CyRPA. The scale graphically represents the normalized quantitative readout of the AVEXIS assay but is not expected to provide relative measures of interaction affinity; values above 0.4 are considered positive. Underlying numerical data can be found in [S1 Data](#pbio.3000490.s009){ref-type="supplementary-material"}. A single representative of three experiments is shown. Anc, ancestral; AVEXIS, avidity-based extracellular interaction screening; CyRPA, cysteine-rich protective antigen; HsBSG, human basigin; Int, introgressed; RH5, reticulocyte-binding protein homologue 5; RIPR, RH5-interacting protein; -ve, negative control.](pbio.3000490.g003){#pbio.3000490.g003}

The gene encoding RH5---although not the other members of the complex---is restricted to the *Laverania* subgenus, suggesting that RH5 and its role in invasion is a recent evolutionary innovation. To date, all binding studies with RH5 complex components have been performed using the *P*. *falciparum* orthologues of these proteins. To determine whether the interactions between the components of the RH5 complex were conserved across the different extant *Laverania* species, we expressed the orthologues of P113 and CyRPA from each of the *Laverania* parasites as bait proteins and tested their ability to bind RH5 prey proteins using the AVEXIS assay. Within each species, we observed that both the RH5-P113 and RH5-CyRPA interactions could be robustly detected ([Fig 3B](#pbio.3000490.g003){ref-type="fig"}). We also asked whether interactions between the orthologues of these proteins from different parasite species could interact by systematically testing them against one another using the AVEXIS assay. We observed that in general, they could, with positive binding observed for all RH5-P113 and RH5-CyRPA combinations, with the exception of *P*. *billcollinsi* RH5, which did not interact with *P*. *adleri* CyRPA ([Fig 3B](#pbio.3000490.g003){ref-type="fig"}). We validated these results by quantifying the binding parameters for a subset using SPR ([S5 Fig](#pbio.3000490.s005){ref-type="supplementary-material"}). These data demonstrate that interactions between the RH5 complex components are conserved within the *Laverania*, and because the RH5-CyRPA interaction is conserved between species, suggest that the co-transfer of the linked *cyrpa* gene was not critical for the zoonotic species jump to humans.

The ability of the introgressed RH5 protein to interact with both gorilla and human basigin was likely to be a critical molecular property in the host switch to human; however, *P*. *falciparum* is restricted to humans and *P*. *falciparum* RH5 only binds human basigin \[[@pbio.3000490.ref021]\]. What, then, were the adaptive changes in the RH5 sequence that likely led to human specialization? There are six amino acid differences between the introgressed and the reference (3D7 strain) *P*. *falciparum* RH5 sequence, some of which are close to the basigin binding site ([Fig 4A](#pbio.3000490.g004){ref-type="fig"} and [S6 Fig](#pbio.3000490.s006){ref-type="supplementary-material"}). To explore the molecular evolutionary changes that led to the loss of gorilla basigin binding, we individually mutated all six residues that differed in the introgressed RH5 sequence to the equivalent residue in the *P*. *falciparum* RH5 sequence, and binding to human and gorilla basigin was quantified by SPR. As expected, all six protein variants bound human basigin and did so with similar affinities ([Fig 4B](#pbio.3000490.g004){ref-type="fig"} and [Fig 4C](#pbio.3000490.g004){ref-type="fig"}). By contrast, the mutation at position 200 resulted in the complete loss of binding to gorilla basigin ([Fig 4B](#pbio.3000490.g004){ref-type="fig"} and [Fig 4C](#pbio.3000490.g004){ref-type="fig"}). These results demonstrate that a single residue was required for the specialization of RH5 binding to human basigin.

![A single amino acid in RH5 is responsible for human basigin binding specialization.\
**(A)** Structural representation of the RH5--basigin complex, with five of the six residues that differ between the introgressed RH5 and *P*. *falciparum* RH5 highlighted in yellow. Note that residue 148 was not resolved in the RH5 structure. **(B)** Proteins corresponding to IntRH5 and the six mutations where the amino acids have been mutated to the corresponding residue in the *P*. *falciparum* RH5 sequence were expressed and purified and the binding to either human or gorilla basigin determined by SPR. Sensorgrams of four 2-fold serial dilutions (600 to 75 nM) are shown, with the raw data shown in black and the fits to a simple 1:1 binding model in red. Representative sensorgrams from two experiments are shown. All mutants bound human basigin with comparable affinity (top row), and one (H200Y) showed no detectable binding to gorilla basigin. **(C)** Calculated interaction half-lives (*t*~1/2~) of all mutants to human and gorilla basigin. Bars represent means ± SEM from at least three different analyte concentrations. Underlying numerical data can be found in [S1 Data](#pbio.3000490.s009){ref-type="supplementary-material"}. IntRH5, introgressed ancestral RH5; RH5, reticulocyte-binding protein homologue 5; SPR, surface plasmon resonance.](pbio.3000490.g004){#pbio.3000490.g004}

Discussion {#sec003}
==========

The discovery that the origins of *P*. *falciparum* are the *Laverania* has raised questions of what determines the strict tropism of these parasites for their gorilla and chimpanzee hosts, and, perhaps more importantly, what were the molecular changes that permitted the zoonotic infection of humans. Anecdotal observations suggesting a molecular restriction factor in the blood stages \[[@pbio.3000490.ref023]\], the identification of an introgression event encoding the essential invasion ligand RH5 \[[@pbio.3000490.ref008],[@pbio.3000490.ref009],[@pbio.3000490.ref016]\], and the specificity of *P*. *falciparum* RH5 binding to human, but not gorilla or chimpanzee basigin \[[@pbio.3000490.ref021]\], all implicated a role for this host--parasite receptor--ligand interaction; however, the molecular pathway triggering the zoonotic infection of humans was unknown.

Our systematic binding studies using the RH5 ligand from the different species within the *Laverania* demonstrate that not all of these parasites rely on host basigin receptor binding specificity to govern host tropism. While the RH5 ligand from clade B parasites, *P*. *billcollinsi* and *P*. *reichenowi*, bound only the basigin receptor from their known hosts, RH5 proteins from the clade A parasites, *P*. *gaboni* and *P*. *adleri*, were more promiscuous and could interact with both the basigin receptor from humans as well as their ape host. This difference provides a molecular explanation for the ability of the ancestor of *P*. *falciparum* to breach species barriers by the inter-clade transfer of a promiscuous "clade A" RH5 ligand that can bind both gorilla and human basigin into an ancestral "clade B" parasite, which likely depended on the specificity of this receptor interaction for host tropism. This finding therefore challenges the general view, based on the binding specificity of *P*. *falciparum* RH5 for human basigin \[[@pbio.3000490.ref021]\], that the host tropism of all *Laverania* parasites is determined by this same mechanism. Given the ability of their RH5 protein to bind the basigin receptor from multiple hosts, it is clear that other factors must determine host tropism for the clade A parasites and *P*. *praefalciparum*. Comparative genome analysis of the *Laverania* parasites suggests likely candidates are also erythrocyte invasion ligands from the Rh and erythrocyte binding antigen families, because the genes within these families are variably present or absent, are pseudogenes, or have multiple paralogues \[[@pbio.3000490.ref008]\]. It is, however, formally possible that other parasite proteins implicated in the adhesion to the red blood cell, such as the merozoite surface proteins (MSPs), or proteins that are important at other stages of the life cycle could be involved.

Coinfections of *Laverania* parasites are frequent in apes \[[@pbio.3000490.ref024],[@pbio.3000490.ref025]\], providing ample opportunity for gene flow between these parasites, and it is highly likely that the founding event encoding *rh5* and *cyrpa* occurred during a coinfection in gorillas. Despite this, comparative genome analysis revealed clear evidence for few introgression events, suggesting they were either very infrequent and/or strongly selected against \[[@pbio.3000490.ref008]\]. By showing that the interactions between the RH5-complex components are conserved across the *Laverania*, we provide an explanation for why this introgression event was tolerated, because a functional RH5 complex is likely to have formed immediately following gene transfer. We can consequently infer that any future gene transfer events involving RH5 complex components are also likely to result in viable recombinant parasites. The finding that there is little binding specificity between the RH5 and CyRPA orthologues from different species also demonstrates that there was no need to preserve binding compatibility between the transferred RH5 and CyRPA proteins, which would have limited any shortening of a possibly larger introgressed region by recombination \[[@pbio.3000490.ref009]\]; rather, our analysis suggests that the cotransfer of *cyrpa* was not critically required.

One intriguing aspect of *Laverania* host--parasite relationships is the restriction of each parasite to a specific host, and it appears that host specialization has occurred multiple times following the clade A/B split \[[@pbio.3000490.ref008]\]. The restriction of *P*. *falciparum* to humans is very likely to have involved changes in the RH5 sequence so that it has become specific for the human basigin receptor \[[@pbio.3000490.ref021]\]. Recent sequence comparisons have identified several codons that may have undergone positive selection in *rh5* during the evolution of the *Laverania*, including three that encode amino acids involved in basigin binding \[[@pbio.3000490.ref026],[@pbio.3000490.ref027]\]. Of these, the residue at position 197 is likely to have changed subsequent to the host switch from gorillas to humans \[[@pbio.3000490.ref026]\], although approximately half of the sequenced Southeast Asian *P*. *falciparum* samples have retained the ancestral tyrosine at this position ([S2 Table](#pbio.3000490.s008){ref-type="supplementary-material"}). In addition, we did not observe any overt difference in binding affinity to human or gorilla basigin between the ancestral protein and the protein with the mutated residue. While the Y197 allele is more frequent in Southeast Asia, the introgressed H148 allele is present in approximately 18% of *P*. *falciparum* isolates, and the Y203 allele is dominant globally, being observed in approximately 86% of sequenced isolates. Conversely, the introgressed RH5 residues H200, R216, and Q219 have not been identified in extant *P*. *falciparum* populations ([S2 Table](#pbio.3000490.s008){ref-type="supplementary-material"}). Here, we have shown that a single substitution at position 200, which is also located within the receptor contact interface, can explain the loss of gorilla basigin binding and thereby restrict *P*. *falciparum* RH5 to the human receptor. Analysis of *P*. *falciparum* genomes from different geographical locations reveals that this allele is fixed in all sequenced isolates \[[@pbio.3000490.ref028]\]. Currently, there is no evidence that fixation of this substitution was positively selected due to enhanced receptor binding because the affinity for human basigin was almost identical between the ancestral and derived allele, and there is no signal of positive selection at this site using interspecific sequence comparisons\[[@pbio.3000490.ref026],[@pbio.3000490.ref027]\]. It is therefore possible that this substitution evolved neutrally, perhaps as a result of a parasite population bottleneck approximately 5,000 years ago \[[@pbio.3000490.ref008]\].

While it seems clear that the horizontal transfer of *rh5* was an important event in the origin of *P*. *falciparum*, there has been discussion as to whether this was a discrete event, whereby a single parasite acquired the ability to exclusively infect humans, or whether it involved a more gradual adaptation in which genetic exchange between the parasite populations in gorillas and humans continued after the introgression event \[[@pbio.3000490.ref008],[@pbio.3000490.ref009]\]. Genome analysis suggests that there was gene flow during this period of adaptation, which eventually ended, causing parasite speciation \[[@pbio.3000490.ref008]\]. Our results provide a molecular mechanism for this multistep process by showing that the introgressed RH5 protein could permit the infection of both gorillas and humans, followed by a mutation at position 200 in RH5 that restricted the parasite to humans. This pathway of adaptation provides an explanation for the presence of ancient dimorphic loci in *P*. *falciparum* isolates that predate the *P*. *falciparum*/*P*. *praefalciparum* last common ancestor \[[@pbio.3000490.ref008]\], and does not invoke the need for a genetic change that would simultaneously permit both switching and restriction to the human host. Finally, malaria remains a major global health problem, and elucidating the molecular events that likely led to the origin of *P*. *falciparum* and their functional effects is of interest not only to understand how this parasite came to cause such a devastating infection of man but also to assess the likelihood, by informed parasite sequence surveillance, of future zoonotic events from the natural reservoir of related parasites.

Materials and methods {#sec004}
=====================

Recombinant protein expression and purification {#sec005}
-----------------------------------------------

*P*. *falciparum* RH5 and its orthologues were expressed as soluble recombinant Cd4-tagged proteins that additionally contained a C-terminal 6-his tag for purification, as previously described \[[@pbio.3000490.ref016]\]. The accession numbers used for proteins sequences were RH5 (PF3D7_0424100), P113 (PF3D7_1420700), CyRPA (PF3D7_0423800), and RIPR (PF3D7_0323400). The additional six *Laverania* RH5 orthologues and introgressed RH5 sequences were synthesized by gene synthesis (Geneart, Germany) essentially as described \[[@pbio.3000490.ref029]\]. The *P*. *blacklocki* genome sequence was derived from just a single isolate that required selective whole genome amplification, resulting in a less complete genome sequence \[[@pbio.3000490.ref008]\]. The expressed recombinant protein corresponding to the *P*. *blacklocki* RH5 orthologue was prone to the formation of aggregates and did not show biological activity by binding gorilla basigin or *P*. *blacklocki* CyRPA or P113, leading us to conclude that there may be errors in the sequence; *P*. *blacklocki* RH5 was therefore excluded from further analysis. To make mutations in the introgressed RH5 sequence, PCR primers were designed with the intended nucleotide change and site-directed mutagenesis performed using KOD Hot Start DNA polymerase (EMD Chemicals, San Diego, CA), as per the manufacturer's instructions. The entire ectodomains of human, chimpanzee, and gorilla basigin were expressed as enzymatically monobiotinylated proteins, as described \[[@pbio.3000490.ref016],[@pbio.3000490.ref021]\]. Genome comparisons of archaic humans, including Neanderthals and Denisovians, showed no polymorphisms affecting the basigin protein sequence in comparison to the *Homo sapiens* reference sequence, suggesting that the host basigin sequence is very likely to have been conserved in hominins over the timescale of the divergence of *P*. *falciparum*. All proteins were expressed as secreted proteins by transient transfection of the human HEK293E cell line grown in suspension as described \[[@pbio.3000490.ref030]\]. When required, proteins were purified from spent tissue culture media using Ni^2+^-NTA resin using an AKTA pure instrument (GE Healthcare, Chicago, IL) \[[@pbio.3000490.ref031]\].

SPR {#sec006}
---

SPR studies were performed using a Biacore 8K instrument (GE Healthcare, Chicago, IL). Biotinylated bait proteins were captured on a streptavidin-coated sensor chip (GE Healthcare, Chicago, IL). Approximately 400 RU of the negative control bait (biotinylated rat Cd4d3+4) were immobilized in the flow cell used as a reference and approximate molar equivalents of the query protein immobilized in other flow cells. Purified analyte proteins were separated by size exclusion chromatography on a Superdex 200 Increase 10/300 column (GE Healthcare, Chicago, IL) in HBS-EP just prior to use in SPR experiments to remove any protein aggregates that might influence kinetic measurements. Increasing concentrations of purified proteins were injected at 100 μL/minute to determine kinetic parameters or at 20 μL/minute for equilibrium measurements. The surface was regenerated with a pulse of 2 M NaCl at the end of each cycle. Duplicate injections of the same concentration in each experiment were superimposable, demonstrating no loss of activity after regenerating the surface. Both kinetic and equilibrium binding data were analyzed in the manufacturer\'s Biacore 8K evaluation software version 1.1 (GE Healthcare, Chicago, IL). Equilibrium binding measurements were taken once equilibrium had been reached, using reference-subtracted sensorgrams. Both the kinetic and equilibrium binding were replicated using independent protein preparations of both ligand and analyte proteins. All experiments were performed at 37 °C in HBS-EP (10 mM HEPES, 150 mM NaCl, 3 mM EDTA, 0.05% v/v P20 surfactant).

AVEXIS {#sec007}
------

Interaction screening was carried out as previously described \[[@pbio.3000490.ref030]\]. Briefly, both bait and prey protein preparations were normalized to activities that have been previously shown to detect transient interactions (monomeric half-lives less than 0.1 second) with a low false positive rate \[[@pbio.3000490.ref015]\]. Biotinylated baits that had been dialyzed against PBS were immobilized in the wells of a streptavidin-coated 96-well microtiter plate (NUNC, Denmark). Normalized preys were added, incubated for 1 hour at room temperature, washed three times in PBS/0.1% Tween-20 and once in PBS, after which 125 μg/mL of nitrocefin (Cayman Chemicals, Ann Arbor, MI) was added and absorbance values measured at 485 nm on a Fluostar Optima (BMG laboratories, Aylesbury, United Kingdom).

Ancestral sequence reconstruction {#sec008}
---------------------------------

The reconstruction of the ancestral sequence of *P*. *falciparum* and *P*. *praefalciparum* for each gene (*rh5*, *cyrpa*, *p113*, and *ripr*) was performed using FastML ([http://fastml.tau.ac.il](http://fastml.tau.ac.il/)). FastML is a program using maximum likelihood and empirical Bayes methods to reconstruct the ancestral characters and compute the posterior probabilities of each ancestral character state. An alignment performed using the translation alignment program available in Geneious v.11. (Biomatters, New Zealand) and including the sequences of all known *Laverania* species (*P*. *falciparum*, *P*. *praefalciparum*, *P*. *reichenowi*, *P*. *billcollinsi*, *P*. *blacklocki*, *P*. *gaboni*, *and P*. *adleri*) was provided for each gene. A maximum likelihood tree for each gene was estimated de novo by the program using a General Time Reversible (GTR) model of molecular evolution. For each sequence, the ancestral reconstruction was performed using two methods: the marginal and the joint reconstruction methods. For the first method, ancestral characters were inferred at the specific node of interest (the node joining *P*. *falciparum* and *P*. *praefalciparum*), while for the second one, all internal node sequences were simultaneously inferred. In all our analyses, both methods provided identical ancestral sequences for the node of interest.

RH5 cell binding assay {#sec009}
----------------------

HEL cells were cultured and probed for binding with RH5 orthologues that were multimerized around streptavidin-phycoerythrin (PE) (Biolegend, San Diego, CA) as described \[[@pbio.3000490.ref022]\]. Briefly, each RH5 orthologue was expressed as a secreted biotinylated monomeric protein with the Cd4(d3+4) tag in HEK293 cells \[[@pbio.3000490.ref016]\]. Spent tissue culture supernatant was dialyzed, serially diluted, and incubated with a fixed streptavidin-PE concentration (1 μg/mL) before transferring complexes to a streptavidin-coated plate (NUNC, Denmark) to determine presence of excess RH5 monomer by ELISA, using OX68 (mouse anti-rat Cd4(d3+4)). To make avid tetramers without excess RH5 monomers for the cell binding assay, the minimal dilution of each RH5 protein was used that demonstrated complete capture by the free streptavidin. Each RH5 tetramer-PE (at 1 μg/mL streptavidin-PE) was incubated with 1 × 10^6^ cells in a total volume of 100 μL for 30 minutes. The cells were washed with PBS and analyzed by flow cytometry. The control anti-CD59 (clone BRIC 229) and blocking anti-basigin Ab-1 \[[@pbio.3000490.ref032]\] antibodies were incubated with the cells for 30 minutes at 10 μg/mL prior to the RH5 tetramer-PE addition.

Structural representation and modeling {#sec010}
--------------------------------------

PyMol 2.0 software (Schrodinger, New York, NY) was used for structural representation and modeling (PDB file 4u0q). The illustrative graphic of the RH5 complex was created using PDB files 4u0q, 5ezo, and 6mpv.

Supporting information {#sec011}
======================

###### Schematic representation of Chromosome 4 in and around the introgressed region.

Each DNA strand is represented by gray bars, and open reading frames encoding the named protein products are colored. The scale indicates the equivalent position in the *P*. *falciparum* 3D7 reference genome. The phylogenetic topologies calculated for the introgressed and flanking sequences are provided, illustrating the extent and origin of the introgressed region.

(TIF)

###### 

Click here for additional data file.

###### Introgressed RH5 and RH5 proteins from extant *Laverania Plasmodium* spp.

The indicated *Laverania* RH5 proteins were expressed in HEK293 cells as secreted recombinant proteins with a Cd4(d3+4)-His^6+^ tag and purified by immobilized Ni^2+^ ion chromatography. Proteins were resolved by SDS-PAGE under reducing conditions and stained with Coomassie brilliant blue. Expected molecular masses: introgressed RH5, 84.9 kDa; *P*. *gaboni*, 85.2 kDa; *P*. *adleri*, 84.9 kDa; *P*. *praefalciparum*, 85.7 kDa; *P*. *falciparum*, 84.7 kDa; *P*. *reichenowi*, 82.5 kDa; *P*. *billcollinsi*, 84.9 kDa. Original unprocessed gels can be found in [S1 Data](#pbio.3000490.s009){ref-type="supplementary-material"}. Cd4(d3+4)-His^6+^, Ig-like domains 3 and 4 of rat CD4; RH5, reticulocyte-binding protein homologue 5.

(TIF)

###### 

Click here for additional data file.

###### RH5 from an ancient inter-clade introgression event in *Laverania* parasites binds a HEL cell line in a basigin-dependent manner.

Binding specificities of *Laverania* parasite RH5 proteins with human basigin were confirmed by cell binding experiments. The introgressed RH5 protein was expressed as an enzymatically monobiotinylated protein, purified, and clustered around a streptavidin-PE conjugate to create an avid RH5 labeled binding probe before presenting to basigin-expressing HEL cells. Specificity was demonstrated by showing that RH5 probe binding activity was abolished by preincubating the cells with an anti-basigin mAb that blocks RH5 binding (Ab1---blue histograms) compared with a cell-binding isotype-matched anti-CD59 mAb (red). Control is streptavidin-PE alone (gray). Summary numerical data are provided in [S1 Data](#pbio.3000490.s009){ref-type="supplementary-material"}; gating strategy and original .fcs files in [S2 Data](#pbio.3000490.s010){ref-type="supplementary-material"}. Ab1, anti-basigin mAb; HEL, human erythroid-like; mAb, monoclonal antibody; PE, phycoerythrin; RH5, reticulocyte-binding protein homologue 5.

(TIF)

###### 

Click here for additional data file.

###### Introgressed RH5 is able to directly interact with introgressed CyRPA and ancestral P113.

SPR traces showing that the introgressed RH5 protein is able to directly interact with the introgressed CyRPA (**A**) and with the known RH5 binding site in the N terminus of P113 (**B**). Both the introgressed CyRPA and N terminus of the ancestral P113 were expressed as soluble enzymatically monobiotinylated proteins and 800 RU and 600 RU were captured, respectively, on the surface of a streptavidin-coated sensor chip. Serial dilutions of purified introgressed RH5 were injected at 100 μL/minute over IntCyRPA (full-length introgressed RH5) and P113Nt (N terminus of introgressed RH5), respectively, and the biophysical binding parameters of the interaction calculated by fitting the binding data (black) to a simple 1:1 binding model (red). Underlying numerical data can be found in [S1 Data](#pbio.3000490.s009){ref-type="supplementary-material"}. CyRPA, cysteine-rich protective antigen; IntCyRPA, introgressed ancestral CyRPA; P113Nt, P113 N-terminal domain; RH5, reticulocyte-binding protein homologue 5; SPR, surface plasmon resonance.

(TIF)

###### 

Click here for additional data file.

###### The interactions between the RH5 complex components are conserved across the *Laverania* subgenus.

**(A)** Representative SPR sensorgrams quantifying the RH5-CyRPA (left panel) and RH5-P113 (right panel) interactions used to calculate the summary data shown in **(B)**. In this example, serial dilutions of *P*. *falciparum* RH5 were used as the analyte with enzymatically monobiotinylated *P*. *falciparum* CyRPA and P113 immobilized on a streptavidin-coated sensor chip. Biophysical binding parameters were calculated by fitting the raw binding data (black) to a simple 1:1 binding model (red). **(B)** A summary of affinity measurements between *P*. *falciparum* (*Pf*) and *P*. *praefalciparum* (*Pp*) RH5 and *P*. *falciparum*, *P*. *praefalciparum*, and *P*. *adleri* CyRPA and P113. The equilibrium dissociation constants (*K*~D~) for each interaction was calculated from 1:1 fits to the SPR binding data and plotted. Bars represent means ± s.e.m. from at least five different analyte concentrations. Underlying numerical data can be found in [S1 Data](#pbio.3000490.s009){ref-type="supplementary-material"}. CyRPA, cysteine-rich protective antigen; *Pf*, *P*. *falciparum*; *Pp*, *P*. *praefalciparum*; RH5, reticulocyte-binding protein homologue 5; SPR, surface plasmon resonance.

(TIF)

###### 

Click here for additional data file.

###### Alignment of the RH5 sequence obtained from the extant species and the estimated ancestral sequence.

Black bars indicate a difference with the ancestral sequence. The red dots indicate a nonsynonymous substitution in *P*. *falciparum* and *P*. *praefalciparum*. RH5, reticulocyte-binding protein homologue 5.

(TIF)

###### 

Click here for additional data file.

###### Table showing the confidence at each residue of the RH5 complex components, RH5, CyRPA, RIPR, and P113.

CyRPA, cysteine-rich protective antigen; RH5, reticulocyte-binding protein homologue 5; RIPR, RH5-interacting protein.

(XLSX)

###### 

Click here for additional data file.

###### Publicly available MalariaGEN data showing non-reference allele frequencies (NRAF) in the *P*. *falciparum* population for RH5.

The introgressed H148 allele is present in 18% of *P*. *falciparum* isolates, while the Y197 allele dominates in Southeast Asia. The Y203 allele is dominant globally (86% of sequenced isolates), making the 3D7 strain unrepresentative for this position. The H200, R216, and Q219 present in the calculated introgressed RH5 sequence have not been detected in extant sequenced *P*. *falciparum* populations. CAF, Central Africa; EAF, East Africa; ESEA, East Southeast Asia; FST, population differentiation statistic; MAF, global allele frequency; NRAF, non-reference allele frequencies; PNG, Papua New Guinea; SAM, South America; SAS, South Asia; WAF, West Africa; WSEA, West South East Asia; RH5, reticulocyte-binding protein homologue 5.

(TIF)

###### 

Click here for additional data file.

###### Contains data pertaining to [Fig 1C](#pbio.3000490.g001){ref-type="fig"}, [Fig 2A](#pbio.3000490.g002){ref-type="fig"}, [Fig 2B](#pbio.3000490.g002){ref-type="fig"}, [Fig 3A](#pbio.3000490.g003){ref-type="fig"}, [Fig 3B](#pbio.3000490.g003){ref-type="fig"}, [Fig 4B](#pbio.3000490.g004){ref-type="fig"}, [Fig 4C](#pbio.3000490.g004){ref-type="fig"}, [S2 Fig](#pbio.3000490.s002){ref-type="supplementary-material"}, [S3 Fig](#pbio.3000490.s003){ref-type="supplementary-material"}, [S4 Fig](#pbio.3000490.s004){ref-type="supplementary-material"}, [S5 Fig](#pbio.3000490.s005){ref-type="supplementary-material"}.

(XLSX)

###### 

Click here for additional data file.

###### Contains flow cytometry gating strategy and original .fcs files for flow cytometry data shown in [Fig 2B](#pbio.3000490.g002){ref-type="fig"} and [S3 Fig](#pbio.3000490.s003){ref-type="supplementary-material"}.

(ZIP)

###### 

Click here for additional data file.

We thank Thomas Otto for sequences.

AVEXIS

:   avidity-based extracellular interaction screening

CyRPA

:   cysteine-rich protective antigen

GTR

:   General Time Reversible

HEL

:   human erythroid-like

IntRH5

:   introgressed ancestral RH5

MSP

:   merozoite surface protein

PE

:   phycoerythrin

Rh

:   reticulocyte-binding homologue

RH5

:   reticulocyte-binding protein homologue 5

RIPR

:   RH5-interacting protein

SPR

:   surface plasmon resonance
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28 Jun 2019

Dear Dr Prugnolle,

Thank you for submitting your manuscript entitled \"Resurrection of the ancestral RH5 invasion ligand provides a molecular explanation for the origin of P. falciparum malaria in humans\" for consideration as a Research Article by PLOS Biology following our presubmission discussion.

Your manuscript has now been evaluated by the PLOS Biology editorial staff as well as by an academic editor with relevant expertise and I am writing to let you know that we would like to send your submission out for external peer review.

However, before we can send your manuscript to reviewers, we need you to complete your submission by providing the metadata that is required for full assessment. To this end, please login to Editorial Manager where you will find the paper in the \'Submissions Needing Revisions\' folder on your homepage. Please click \'Revise Submission\' from the Action Links and complete all additional questions in the submission questionnaire.

\*\*Important\*\*: Please also see below for further information regarding completing the MDAR reporting checklist. The checklist can be accessed here: <https://plos.io/MDARChecklist>

Please re-submit your manuscript and the checklist, within two working days, i.e. by Jun 30 2019 11:59PM.

Login to Editorial Manager here: <https://www.editorialmanager.com/pbiology>

During resubmission, you will be invited to opt-in to posting your pre-review manuscript as a bioRxiv preprint. Visit <http://journals.plos.org/plosbiology/s/preprints> for full details. If you consent to posting your current manuscript as a preprint, please upload a single Preprint PDF when you re-submit.

Once your full submission is complete, your paper will undergo a series of checks in preparation for peer review. Once your manuscript has passed all checks it will be sent out for review.

Feel free to email us at <plosbiology@plos.org> if you have any queries relating to your submission.

Kind regards,

Lauren A Richardson, Ph.D

Senior Editor

PLOS Biology

==================

INFORMATION REGARDING THE REPORTING CHECKLIST:

PLOS Biology is pleased to support the \"minimum reporting standards in the life sciences\" initiative (<https://osf.io/preprints/metaarxiv/9sm4x/>). This effort brings together a number of leading journals and reproducibility experts to develop minimum expectations for reporting information about Materials (including data and code), Design, Analysis and Reporting (MDAR) in published papers. We believe broad alignment on these standards will be to the benefit of authors, reviewers, journals and the wider research community and will help drive better practise in publishing reproducible research.

We are therefore participating in a community pilot involving a small number of life science journals to test the MDAR checklist. The checklist is intended to help authors, reviewers and editors adopt and implement the minimum reporting framework.

IMPORTANT: We have chosen your manuscript to participate in this trial. The relevant documents can be located here:

MDAR reporting checklist (to be filled in by you): <https://plos.io/MDARChecklist>

\*\*We strongly encourage you to complete the MDAR reporting checklist and return it to us with your full submission, as described above. We would also be very grateful if you could complete this author survey:

<https://forms.gle/seEgCrDtM6GLKFGQA>

Additional background information:

Interpreting the MDAR Framework: <https://plos.io/MDARFramework>

Please note that your completed checklist and survey will be shared with the minimum reporting standards working group. However, the working group will not be provided with access to the manuscript or any other confidential information including author identities, manuscript titles or abstracts. Feedback from this process will be used to consider next steps, which might include revisions to the content of the checklist. Data and materials from this initial trial will be publicly shared in September 2019. Data will only be provided in aggregate form and will not be parsed by individual article or by journal, so as to respect the confidentiality of responses.

Please treat the checklist and elaboration as confidential as public release is planned for September 2019.

We would be grateful for any feedback you may have.

10.1371/journal.pbio.3000490.r002
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31 Jul 2019

Dear Dr Prugnolle,

Thank you very much for submitting your manuscript \"Resurrection of the ancestral RH5 invasion ligand provides a molecular explanation for the origin of P. falciparum malaria in humans\" for consideration as a Research Article at PLOS Biology. Your manuscript has been evaluated by the PLOS Biology editors, an Academic Editor with relevant expertise, and by several independent reviewers.

In light of the reviews (below), we are pleased to offer you the opportunity to address the comments from the reviewers in a revised version that we anticipate should not take you very long. Of particular note, the reviewers request a more robust introduction and a more nuanced discussion of the results. Rev \#2 also raises an important point about variation within Plasmodium sequences.

Your revisions should address the specific points made by each reviewer. Please submit a file detailing your responses to the editorial requests and a point-by-point response to all of the reviewers\' comments that indicates the changes you have made to the manuscript. In addition to a clean copy of the manuscript, please upload a \'track-changes\' version of your manuscript that specifies the edits made. This should be uploaded as a \"Related\" file type. You should also cite any additional relevant literature that has been published since the original submission and mention any additional citations in your response.

Please note while forming your response, if your article is accepted, you may have the opportunity to make the peer review history publicly available. The record will include editor decision letters (with reviews) and your responses to reviewer comments. If eligible, we will contact you to opt in or out.

Before you revise your manuscript, please review the following PLOS policy and formatting requirements checklist PDF: <http://journals.plos.org/plosbiology/s/file?id=9411/plos-biology-formatting-checklist.pdf>. It is helpful if you format your revision according to our requirements - should your paper subsequently be accepted, this will save time at the acceptance stage.

Please note that as a condition of publication PLOS\' data policy (<http://journals.plos.org/plosbiology/s/data-availability>) requires that you make available all data used to draw the conclusions arrived at in your manuscript. If you have not already done so, you must include any data used in your manuscript either in appropriate repositories, within the body of the manuscript, or as supporting information (N.B. this includes any numerical values that were used to generate graphs, histograms etc.). For an example see here: <http://www.plosbiology.org/article/info%3Adoi%2F10.1371%2Fjournal.pbio.1001908#s5>.

For manuscripts submitted on or after 1st July 2019, we require the original, uncropped and minimally adjusted images supporting all blot and gel results reported in an article\'s figures or Supporting Information files. We will require these files before a manuscript can be accepted so please prepare them now, if you have not already uploaded them. Please carefully read our guidelines for how to prepare and upload this data: <https://journals.plos.org/plosbiology/s/figures#loc-blot-and-gel-reporting-requirements>.

Upon resubmission, the editors assess your revision and assuming the editors and Academic Editor feel that the revised manuscript remains appropriate for the journal, we may send the manuscript for re-review. We aim to consult the same Academic Editor and reviewers for revised manuscripts but may consult others if needed.

We expect to receive your revised manuscript within one month. Please email us (<plosbiology@plos.org>) to discuss this if you have any questions or concerns, or would like to request an extension. At this stage, your manuscript remains formally under active consideration at our journal; please notify us by email if you do not wish to submit a revision and instead wish to pursue publication elsewhere, so that we may end consideration of the manuscript at PLOS Biology.

When you are ready to submit a revised version of your manuscript, please go to <https://www.editorialmanager.com/pbiology/> and log in as an Author. Click the link labelled \'Submissions Needing Revision\' where you will find your submission record.

Thank you again for your submission to our journal. We hope that our editorial process has been constructive thus far, and we welcome your feedback at any time. Please don\'t hesitate to contact us if you have any questions or comments.

Sincerely,

Lauren A Richardson, Ph.D

Senior Editor

PLOS Biology

\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*

Reviews

Reviewer \#1:

Galaway and co-authors describe their efforts to recreate and phenotype an ancestral version of a protein (Rh5) that mediates red blood cell invasion by malaria parasites and is thought to have been a crucial player in the origin of P. falciparum as a human parasite through an introgression event from a gorilla parasite lineage. This approach taken by the authors to express extant and ancestral versions of the Rh5 protein is elegant, and the authors employ both SPR and cell-based assays to produce robust phenotype profiles. This work is an important addition to the exciting recent advances in understanding the origins of human malaria and the role of red blood cell invasion in host tropism.

The manuscript is clearly written and the authors' conclusions are generally well supported. I have the following questions and suggestions for minor clarifications:

1\) The ancestral gene reconstruction for IntRH5 is included in a supplemental table, but a cursory description of how divergent it is from extant Pfal/Padleri/Ppraefalciparum sequences in the main text would be useful. How many amino acid subs from extant species? It could be useful, for example, to see a small tree showing the subs that have subsequently occurred on the Pfal/Pprae lineages since introgression to understand the rough magnitude of divergence that has subsequently occurred.

2\) On a similar note, near the end of Results the authors mention 6 AA differences between the introgressed and reference 3D7 assembly sequence for Rh5. It would be helpful to clarify here whether 3D7 is expected to reflect ancestral or derived alleles at these positions for P. falciparum, given that Rh5 is polymorphic in contemporary parasite populations (albeit lowly relative to other invasion genes).

3\) The Discussion does not remark upon an observation one can make by comparing Figures 2A and 4B: that contemporary Pprae Rh5 is better at binding both human and gorilla basigen than the inferred introgressed allele (IntRH5). IntRH5 appears to have been a fairly poor binder to gorilla basigen, in fact, suggesting that subsequent adaption within the Ppra lineage may have been necessary to achieve more effective infection of gorillas following an introgression event and selective sweep driven by the capacity to successfully infect humans. This is a surprising finding, perhaps indicating that the introgression event subsumed a presumed pre-existing chimp host tropism in the Pf/Pprae ancestral lineage due to the evolutionary advantage arising from the capacity to infect humans.

\-\-\-\-\-\-\-\-\-\-\-\-\-\--

Reviewer \#2:

In their manuscript entitled "Resurrection of the ancestral RH5 invasion ligand provides a molecular explanation for the origin of P. falciparum malaria in humans" the authors seek to show how Plasmodium parasites may have switched hosts, evolving from a gorilla-specific parasite to one that can infection humans (Plasmodium falciparum). To do this, they "resurrect" the introgressed ancestral RH5 gene, which encodes the ligand which enables erythrocyte invasion by binding the basigin receptor, and conduct protein interaction assays to test binding. By doing so, they show that the ancestral P. falciparum RH5 gene can bind various receptors. Furthermore, they show that specificity to one species, or more precisely loss of specificity to a species, can arise from point mutations in the sequence. The study provides interesting molecular data to support the hypothesis that human specificity evolved via changes in rh5.

The manuscript is well written and the authors provide compelling biochemical binding data. On the other hand, tests with recombinant proteins do not really tell you whether the mutations will have the same function in the context of an infection with other proteins present. Should one try swapping expression of P. falciparum rh5 with ancestral rh5 using a conditional knockdown system (for example, with a tet aptamer system, degradation domain), and test to see if this changes affinity for human erythrocytes? Such experiments are difficult and may be outside the scope of this study, however.

In addition, the authors focus on a single 3D7 sequence and there may be other rh5 and basigin gene variants present in their respective human and parasite populations. The authors state that there are only six nonsynonymous changes between the P. falciparum rh5 and rh5 introgressed sequence and yet there seem to be more than six nonsynonymous rh5 mutations within existing P. falciparum populations (e.g. those present in PlasmoDB), and some of these variants are present in the introgressed rh5 variant (positions 148, 197, 203). Would the authors' results be different if the authors used different P. falciparum sequences? Although the 3D7 strain is the most heavily studied, it may or may not be a good representative for studies on species evolution. Do any of the phylogenetic trees change if one uses different strains?

Minor points:

The introduction is somewhat brief and to understand this, additional background reading is needed. If length is not a constraint, this could be expanded. For example, are there additional known functions of P113, RIPR, CyRPA (only presented interactions with RH5, but what does interaction entail); knock-out studies, overexpression studies, conserved regions/homology between species?

Please elaborate on how rh5 might be druggable, since this is mentioned. Would this be by disrupting protein interactions? Are there many drugs that work this way? Would an rh5 drug work against many different rh5 isolates?

Briefly state how was the sequence of the ancestral RH5 determined in the text to aid readability.

Briefly elaborate on the surface binding assay in the results. The reader currently needs to go to the methods and other publications to understand this.

Briefly explain what an introgressed sequence is.

The authors write, "Interestingly, the introgressed fragment encompassed two genes encoding RH5 complex components: RH5 and CyRPA, which are genetically closely linked (Fig. 1A)." but there seems to be no evidence provided in Fig 1A that RH5 and CyRPA are genetically closely linked. How many bases separate the two? Some sort of diagram or specifics would help the reader understand what is happening.

Discussio: In the discussion of mutating residues, would be good consider that there are different variants for some of these residues in existing population genomic datasets for P. falciparum.

Discussion: Mention if host tropism could be determined by proteins other than the RH and EBA family proteins?

Figure 1A: what do blue, black, red figures refer to (can be inferred, but better explicit)

Figure 1A: A better description of how the dendrogram was created would be useful. Could a reference be provided?

Figure 1B: Rh5 is drawn so the N- and C-terminal parts are separate, which is confusing. As drawn it also looks like there is no contact between the erythrocyte and the parasite, forcing one to go look at the existing literature. Perhaps a schematic diagram could be given?

Figure 3B: Include clade information

Figure 4A: where is the binding region between RH5 and basigin? Can the authors circle or highlight this region?

Please provide Kd values plus error bars for Figure 2B.

It would be useful if the authors included the Plasmodium systematic names for proteins that are discussed in Figures and text, given that there can sometimes be multiple names in the literature.

Figure S1: title is redundant with text.

Figure 2 and Table S1. It would be useful to comment that the results are from flow cytometry. The X axis could read PE fluorescence of flow sorted HEL cells as well to make the data clearer. A diagram of the experimental setup would be even better.

\-\-\-\-\-\-\-\-\-\-\-\-\-\--

Reviewer \#3:

This very interesting article. Particularly the fact that P. gaboni shows promiscuous affinity whereas P. blacklocki that also is found in gorillas did not. Could be possible that the so-called clade B is indeed a group of parasites that can infect chimpanzees? Please clarify.

Nevertheless, the invasion of P. falciparum is a process that we are just starting to understand and there could be other mechanisms involved. Particularly the role of the Rh5--CyRPA--Ripr complex. I suggest checking Wang et al. 2019 Nature 565: 118--121 and discuss their results in that context. I also suggest checking Volz et al 2016 Cell Host Microbe, 20, 60--71. It will be also interesting to discuss, even as a speculation (the authors may not have a way of testing), the role that antibodies may have in inhibiting the process (Healer et al 2019 Cellular Microbiology 21: e13030) and suggest that such experiments could be of interest. Sometimes less efficient binding still suffices to mediate invasion. Although the information is valuable, it may not tell the complete story so the manuscript will improve by adding a more critical discussion of the findings.

10.1371/journal.pbio.3000490.r003

Author response to Decision Letter 1

28 Aug 2019

###### 

Submitted filename: Galaway_PbP_PLoSB.pdf

###### 

Click here for additional data file.

10.1371/journal.pbio.3000490.r004
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3 Sep 2019

Dear Dr Wright,

Thank you for submitting your revised Research Article entitled \"Resurrection of the ancestral RH5 invasion ligand provides a molecular explanation for the origin of P. falciparum malaria in humans\" for publication in PLOS Biology.

The Academic Editor and I have now assessed your revised manuscript and we\'re delighted to let you know that we\'re now editorially satisfied with your manuscript. We will publish your study, assuming you are willing to make the final edits to meet our production requirements. Congratulations!

Before we can formally accept your paper and consider it \"in press\", we also need to ensure that your article conforms to our guidelines. A member of our team will be in touch shortly with a set of requests. As we can\'t proceed until these requirements are met, your swift response will help prevent delays to publication.

Upon acceptance of your article, your final files will be copyedited and typeset into the final PDF. While you will have an opportunity to review these files as proofs, PLOS will only permit corrections to spelling or significant scientific errors. Therefore, please take this final revision time to assess and make any remaining major changes to your manuscript.

Please note that you may have the opportunity to make the peer review history publicly available. The record will include editor decision letters (with reviews) and your responses to reviewer comments. If eligible, we will contact you to opt in or out.

Please note that an uncorrected proof of your manuscript will be published online ahead of the final version, unless you opted out when submitting your manuscript. If, for any reason, you do not want an earlier version of your manuscript published online, uncheck the box. Should you, your institution\'s press office or the journal office choose to press release your paper, you will automatically be opted out of early publication. We ask that you notify us as soon as possible if you or your institution is planning to press release the article.

To submit your revision, please go to <https://www.editorialmanager.com/pbiology/> and log in as an Author. Click the link labelled \'Submissions Needing Revision\' to find your submission record. Your revised submission must include a cover letter, a Response to Reviewers file that provides a detailed response to the reviewers\' comments (if applicable), and a track-changes file indicating any changes that you have made to the manuscript.

Please do not hesitate to contact me should you have any questions.

Sincerely,

Lauren A Richardson, Ph.D

Senior Editor

PLOS Biology

\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\--

DATA POLICY:

You may be aware of the PLOS Data Policy, which requires that all data be made available without restriction: <http://journals.plos.org/plosbiology/s/data-availability>. For more information, please also see this editorial: <http://dx.doi.org/10.1371/journal.pbio.1001797>

Note that we do not require all raw data. Rather, we ask that all individual quantitative observations that underlie the data summarized in the figures and results of your paper be made available in one of the following forms:

1\) Supplementary files (e.g., excel). Please ensure that all data files are uploaded as \'Supporting Information\' and are invariably referred to (in the manuscript, figure legends, and the Description field when uploading your files) using the following format verbatim: S1 Data, S2 Data, etc. Multiple panels of a single or even several figures can be included as multiple sheets in one excel file that is saved using exactly the following convention: S1_Data.xlsx (using an underscore).

2\) Deposition in a publicly available repository. Please also provide the accession code or a reviewer link so that we may view your data before publication.

Regardless of the method selected, please ensure that you provide the individual numerical values that underlie the summary data displayed in the following figure panels: (e.g. Figs. 3AB, 4C, S5B), as they are essential for readers to assess your analysis and to reproduce it. Please also ensure that figure legends in your manuscript include information on where the underlying data can be found.

For figures containing FACS data, we ask that you provide FCS files and a picture showing the successive plots and gates that were applied to the FCS files to generate the figure.

Please ensure that your Data Statement in the submission system accurately describes where your data can be found.

\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\--

BLOT AND GEL REPORTING REQUIREMENTS:

For manuscripts submitted on or after 1st July 2019, we require the original, uncropped and minimally adjusted images supporting all blot and gel results reported in an article\'s figures or Supporting Information files. We will require these files before a manuscript can be accepted so please prepare them now, if you have not already uploaded them. Please carefully read our guidelines for how to prepare and upload this data: <https://journals.plos.org/plosbiology/s/figures#loc-blot-and-gel-reporting-requirements>.
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12 Sep 2019

Dear Dr Wright,

On behalf of my colleagues and the Academic Editor, Andrew Fraser Read, I am pleased to inform you that we will be delighted to publish your Research Article in PLOS Biology.

The files will now enter our production system. You will receive a copyedited version of the manuscript, along with your figures for a final review. You will be given two business days to review and approve the copyedit. Then, within a week, you will receive a PDF proof of your typeset article. You will have two days to review the PDF and make any final corrections. If there is a chance that you\'ll be unavailable during the copy editing/proof review period, please provide us with contact details of one of the other authors whom you nominate to handle these stages on your behalf. This will ensure that any requested corrections reach the production department in time for publication.

Early Version

The version of your manuscript submitted at the copyedit stage will be posted online ahead of the final proof version, unless you have already opted out of the process. The date of the early version will be your article\'s publication date. The final article will be published to the same URL, and all versions of the paper will be accessible to readers.

PRESS

We frequently collaborate with press offices. If your institution or institutions have a press office, please notify them about your upcoming paper at this point, to enable them to help maximise its impact. If the press office is planning to promote your findings, we would be grateful if they could coordinate with <biologypress@plos.org>. If you have not yet opted out of the early version process, we ask that you notify us immediately of any press plans so that we may do so on your behalf.

We also ask that you take this opportunity to read our Embargo Policy regarding the discussion, promotion and media coverage of work that is yet to be published by PLOS. As your manuscript is not yet published, it is bound by the conditions of our Embargo Policy. Please be aware that this policy is in place both to ensure that any press coverage of your article is fully substantiated and to provide a direct link between such coverage and the published work. For full details of our Embargo Policy, please visit <http://www.plos.org/about/media-inquiries/embargo-policy/>.

Thank you again for submitting your manuscript to PLOS Biology and for your support of Open Access publishing. Please do not hesitate to contact me if I can provide any assistance during the production process.

Kind regards,

Alice Musson

Publication Assistant,

PLOS Biology

on behalf of

Lauren Richardson,

Senior Editor

PLOS Biology
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